1-6 of 204 Activities
In the fourth activity of this CME Outfitters Snack series, expert faculty from the United States, Europe, Africa, and Asia will discuss using patient engagement and working with patients collaboratively to promote worldwide PrEP initiation and adherence strategies.
In the second activity of this CME Outfitters Snack series, expert faculty from the United States, Europe, Africa, and Asia will discuss the latest information on PrEP options for HIV, including efficacy, safety, MOAs and modes of administration.
In the first activity of this CME Outfitters Snack series, expert faculty from the United States, Europe, Africa, and Asia will discuss how to develop tailored strategies that address barriers to status-neutral HIV screening and effective HIV prevention strategies such as PrEP.
In this CMEO BriefCase, expert faculty will walk learners through a real-world case, stopping for strategic discussions on the assessment of data on available anti-CD20 therapies to make appropriate recommendations for patients with MS, utilization of evidence-based guidelines for MS management to optimize treatment selection and monitor therapeutic outcomes, and the development of tailored MS treatment plans to address the unique physiological and social needs of older and pediatric patients.
Generalized myasthenia gravis (gMG) disrupts neuromuscular transmission, creating unpredictable symptom flare-ups and placing a significant burden on patients with this rare condition. Most commonly associated with antibodies targeting the acetylcholine receptor (AChR), and less commonly with muscle specific kinase (MuSK) or low-density lipoprotein receptor–related protein 4 (LRP4), gMG has forced patients and clinicians to navigate treatments that can be difficult to tolerate, slow to act, or limited by safety concerns. The expanding availability of neonatal Fc receptor (FcRn) blockers has introduced targeted options designed to reduce pathogenic IgG and improve symptoms. Clinicians, however, lack practical, evidence-based guidance on optimizing FcRn antagonist regimens in partial responders, including interval adjustments, transitions between cyclic and consistent dosing, structured monitoring, and safe steroid tapering, which results in persistent symptoms and avoidable treatment burden. Clinicians and multidisciplinary care teams require rigorous education in optimized dosing and longitudinal management to transform the care experience for patients with gMG.
In the second activity of this CME Outfitters BriefCase series, expert faculty will differentiate MOAs, safety, and efficacy profiles of currently approved FcRn antagonists for the treatment of gMG. Faculty will incorporate strategies to identify patients with gMG who may be appropriate candidates for treatment with FcRn antagonists, and utilize an individualized approach to treatment planning for patients with gMG receiving FcRn antagonists based on the latest data as well as patient preferences.
In the first activity of this CME Outfitters BriefCase series, expert faculty will differentiate MOAs, safety considerations, and efficacy data of currently approved FcRn antagonists for the treatment of gMG. Faculty will incorporate strategies to identify patients with gMG who may be appropriate candidates for FcRn antagonist therapy, and apply an individualized approach to treatment planning based on available evidence and patient preferences.